Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986447 in Healthy Adults
NCT05760937Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases comparing BMS-986447 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events (AEs) up to 59 days, Number of Participants with Serious AEs (SAEs) up to 59 days and 4 more. Started Mar 2023; status: completed.
02
Drugs
BMS-986447
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT05760937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760937.